Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1.
Acute myeloid leukemia
All-trans-retinoic acid
EVI1
Leukemia stem cells
MECOM
Journal
Oncology and therapy
ISSN: 2366-1089
Titre abrégé: Oncol Ther
Pays: New Zealand
ID NLM: 101677510
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
09
01
2019
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
24
7
2020
Statut:
ppublish
Résumé
EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. In this pilot study, we investigated the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Seven of the 13 patients (53.8%) achieved complete remission (CR), and response can be combined with a decreased of the leukemia stem cell pool. These primary results tend to confirm in vitro results and suggest that addition of ATRA might be of benefit in the treatment of patients with EVI1-positive AML.
Identifiants
pubmed: 32699982
doi: 10.1007/s40487-019-0095-9
pii: 10.1007/s40487-019-0095-9
pmc: PMC7359977
doi:
Types de publication
Journal Article
Langues
eng
Pagination
121-130Références
Hematol J. 2002;3(1):49-55
pubmed: 11960396
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Exp Hematol. 2017 Aug;52:12-23
pubmed: 28456748
Blood. 2003 Feb 1;101(3):837-45
pubmed: 12393383
Cell Stem Cell. 2008 Aug 7;3(2):207-20
pubmed: 18682242
Blood. 2015 May 28;125(22):3455-65
pubmed: 25795919
Haematologica. 2011 Oct;96(10):1448-56
pubmed: 21750091
Leuk Lymphoma. 2017 Oct;58(10):2426-2438
pubmed: 28276286
JAMA. 2010 Dec 22;304(24):2706-15
pubmed: 21177505
Leukemia. 1997 Feb;11(2):212-20
pubmed: 9009083
J Exp Med. 2016 Apr 4;213(4):483-97
pubmed: 26951332
J Cell Biochem. 2006 Apr 15;97(6):1328-38
pubmed: 16329108
Blood. 2011 Jan 6;117(1):234-41
pubmed: 20855866
Ann Hematol. 2016 Dec;95(12):1931-1942
pubmed: 27696203
J Clin Oncol. 2010 Feb 1;28(4):586-95
pubmed: 20038732
Int Immunol. 2018 Jul 24;30(8):375-383
pubmed: 29868798
Nat Med. 2008 Dec;14(12):1333-42
pubmed: 19029980
Blood. 2016 Jan 28;127(4):458-63
pubmed: 26582376
Blood. 2006 Jun 15;107(12):4614-22
pubmed: 16484584
Leukemia. 2005 Dec;19(12):2241-6
pubmed: 16239915
Blood. 2016 Jun 9;127(23):2867-78
pubmed: 27103744
Nat Med. 2012 Mar 11;18(4):605-11
pubmed: 22406747
Cell Cycle. 2014;13(18):2931-43
pubmed: 25486480
Int J Stem Cells. 2018 May 30;11(1):131-140
pubmed: 29699387
Leukemia. 2004 Nov;18(11):1798-803
pubmed: 15385923
Cancer Res. 2018 May 15;78(10):2601-2613
pubmed: 29487199
J Clin Oncol. 2010 Aug 20;28(24):3890-8
pubmed: 20660833
Blood. 1999 Apr 15;93(8):2478-84
pubmed: 10194425
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
J Clin Oncol. 2010 Apr 20;28(12):2101-7
pubmed: 20308656
World J Stem Cells. 2017 Dec 26;9(12):227-234
pubmed: 29321824
Br J Haematol. 2016 Mar;172(6):870-8
pubmed: 26729571
Mol Cell Biol. 2006 Oct;26(20):7658-66
pubmed: 16954386
Blood. 1990 Nov 1;76(9):1704-9
pubmed: 2224119
J Exp Med. 2013 Apr 8;210(4):647-53
pubmed: 23509325
Cancer. 2007 Mar 15;109(6):1114-24
pubmed: 17315155
Bone Marrow Transplant. 2016 Jul;51(7):921-7
pubmed: 27042849